Redwood City, California-based Versartis is developing a once-monthly form of recombinant human growth hormone (rhGH) to treat growth hormone deficiency (GHD) in children. The company is running a Phase IIa clinical trial for its lead program VRS-317 to…
written on 18.02.2014
BioNotebook: Versartis VC funding, IPO filing; ANI 2013 earnings; Cardiome's ATM; Eleven's Phase III
